Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has over 32 additional generic prescription drugs. In addition, the Company is conducting a proprietary drug development program which consists of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections.
The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio of pharmaceutical products consisting of approximately 61 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 113.0K |
| Three Month Average Volume | 2.8M |
| High Low | |
| Fifty-Two Week High | 895.8 USD |
| Fifty-Two Week Low | 2.42 USD |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 08 Aug 2024 |
| Price and Volume | |
| Current Price | 2.84 USD |
| Beta | -1 |
| Relative Price Change | |
| Four Week Relative Price Change | -42.53% |
| Thirteen Week Relative Price Change | -78.82% |
| Twenty-Six Week Relative Price Change | -97.67% |
| Fifty-Two Week Relative Price Change | -99.74% |
| Year-to-Date Relative Price Change | -99.56% |
| Price Change | |
| One Day Price Change | 1.43% |
| Thirteen Week Price Change | -77.33% |
| Twenty-Six Week Price Change | -97.44% |
| Five Day Price Change | -6.89% |
| Fifty-Two Week Price Change | -99.67% |
| Year-to-Date Price Change | -99.48% |
| Month-to-Date Price Change | -47.23% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1513.73 USD |
| Book Value Per Share (Most Recent Quarter) | 20.06806 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1410.642 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 17.97741 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -148.983 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1979.687 USD |
| Revenue Per Share (Trailing Twelve Months) | 1017.848 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -370.3815 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -194.0078 USD |
| Normalized (Last Fiscal Year) | -370.3815 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -370.3815 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -194.0078 USD |
| Including Extraordinary Items (Last Fiscal Year) | -370.3815 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -194.0078 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1162.909 USD |
| Cash Per Share (Most Recent Quarter) | 9.8314 USD |
| Cash Flow Per Share (Last Fiscal Year) | -358.0025 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -117.0896 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -417.31 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -63 |
| Cash Flow Revenue (Trailing Twelve Months) | -41 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -12.27% |
| Pretax Margin (Last Fiscal Year) | -17.06% |
| Pretax Margin (5 Year) | -163.15% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 34.61% |
| Gross Margin (Trailing Twelve Months) | 30.41% |
| Gross Margin (5 Year) | 35.47% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -19.86% |
| Operating Margin (Trailing Twelve Months) | -15.20% |
| Operating Margin (5 Year) | -165.05% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -18.70% |
| Net Profit Margin (Trailing Twelve Months) | -12.07% |
| Net Profit Margin (5 Year) | -165.33% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 67.30% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 109.82% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | 596.16% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 110.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 86.03% |
| EPS Change (Trailing Twelve Months) | 92.14% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 0 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -11,507,750 |
| Net Debt (Last Fiscal Year) | -16,292,350 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 0 |
| Price to Sales (Trailing Twelve Months) | 0 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 3 |
| Quick Ratio (Most Recent Quarter) | 3 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 5 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -9,563,210 |
| Free Cash Flow (Trailing Twelve Months) | -12,497,390 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -15.92% |
| Return on Assets (Trailing Twelve Months) | -12.75% |
| Return on Assets (5 Year) | -101.52% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -21.04% |
| Return on Equity (Trailing Twelve Months) | -15.80% |
| Return on Equity (5 Year) | -156.16% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -20.43% |
| Return on Investment (Trailing Twelve Months) | -15.41% |
| Return on Investment (5 Year) | -137.04% |